The non-residualizing [125I]I-HPEM label provided the highest tumor-to-muscle and tumor-to-bone ratios 3 h p.i. and is the most suitable for imaging of EpCAM in the early stages of prostate cancer. This evidence concerns the gene EPCAM and prostate cancer.